Synthesis of Sitagliptin phosphate monohydrate as Orally Treatment for Type-۲ Diabet

Due to the world health organization (WHO) reports, Type-۲ diabetes is considered as a serious problem for human health. In this regards, our team work tried to synthesis of sitagliptin as one of the important DPP-۴ inhibitors in pharmaceutically acceptable salt form, sitagliption phosphate monohydrate. The quality and physicochemical properties of synthesized samples were investigated using various methods such as UV–vis, FT-IR, ۱H-NMR and ۱۳C-NMR as well as purity evaluation by high- performance liquid chromatography (HPLC). In our mild and environmentally- friendly process, sitagliption phosphate monohydrate was synthesized in high purity (more than ۹۹%) and high yield (about ۱.۲% based on sitagliptin base weight) required for pharmaceutical use.

Keywords:

Type-۲ Diabet , Sitagliptin , Sitagliption phosphate monohydrate , Dipeptidyl peptidase IV (DPP-۴) inhibitor